626 related articles for article (PubMed ID: 30232410)
21. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
[TBL] [Abstract][Full Text] [Related]
22. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis.
Feng Y; Mischler WJ; Gurung AC; Kavanagh TR; Androsov G; Sadow PM; Herbert ZT; Priolo C
Cancer Res; 2020 Jul; 80(13):2751-2763. PubMed ID: 32393662
[TBL] [Abstract][Full Text] [Related]
24. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas.
Henske EP; Neumann HP; Scheithauer BW; Herbst EW; Short MP; Kwiatkowski DJ
Genes Chromosomes Cancer; 1995 Aug; 13(4):295-8. PubMed ID: 7547639
[TBL] [Abstract][Full Text] [Related]
25. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
27. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
28. Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (TSC1) tuberous sclerosis family.
Sampson JR; Patel A; Mee AD
J Med Genet; 1995 Nov; 32(11):848-50. PubMed ID: 8592324
[TBL] [Abstract][Full Text] [Related]
29. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
30. Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
Li C; Liu X; Liu Y; Zhang E; Medepalli K; Masuda K; Li N; Wikenheiser-Brokamp KA; Osterburg A; Borchers MT; Kopras EJ; Plas DR; Sun J; Franz DN; Capal JK; Mays M; Sun Y; Kwiatkowski DJ; Alayev A; Holz MK; Krueger DA; Siroky BJ; Yu JJ
Mol Cancer Res; 2017 Oct; 15(10):1318-1330. PubMed ID: 28710231
[TBL] [Abstract][Full Text] [Related]
31. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
32. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.
Back SJ; Andronikou S; Kilborn T; Kaplan BS; Darge K
Pediatr Radiol; 2015 Mar; 45(3):386-95. PubMed ID: 25355409
[TBL] [Abstract][Full Text] [Related]
33. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
35. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
36. Genotype/phenotype correlation in 123 Chinese patients with Tuberous Sclerosis Complex.
Ng SY; Luk HM; Hau EW; Cheng SS; Yu KP; Ho S; Mok MT; Lo IF
Eur J Med Genet; 2022 Oct; 65(10):104573. PubMed ID: 35918040
[TBL] [Abstract][Full Text] [Related]
37. The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked?
Henske EP
Curr Mol Med; 2004 Dec; 4(8):825-31. PubMed ID: 15579029
[TBL] [Abstract][Full Text] [Related]
38. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
39. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.
Inoki K; Guan KL
Hum Mol Genet; 2009 Apr; 18(R1):R94-100. PubMed ID: 19297407
[TBL] [Abstract][Full Text] [Related]
40. Low-level mosaicism in tuberous sclerosis complex in four unrelated patients: Comparison of clinical characteristics and diagnostic pathways.
Manzanilla-Romero HH; Weis D; Schnaiter S; Rudnik-Schöneborn S
Am J Med Genet A; 2021 Dec; 185(12):3851-3858. PubMed ID: 34328706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
